Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

Hidradenitis Suppurativa (HS) is getting increased attention from dermatologists due to its frequent misdiagnosis and ...

Study authors examined the relationship between the use of combined oral contraceptives and the onset of hidradenitis suppurativa.

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

Benzoyl peroxide is one of the most effective and commonly used acne treatments. You’ll find it in prescription and ...

Fewer than half of respondents (46.9%) had a dermatologist as their primary ... in a large cohort with hidradenitis suppurativa. In Patients with HS, a Closer Look at Stigmatization and Perceived ...

Christopher J. Sayed, MD, reports on how the 2025 American Academy of Dermatology Annual Meeting was an exciting event for hidradenitis suppurativa (HS), with increasing buzz and interest in the ...

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.